Amgen's Strategic Moves Amidst U.S.-China Biotech Tensions

Amgen’s Strategic Moves Amidst U.S.-China Biotech Tensions

In the past week, the U.S. biopharmaceutical industry has been grappling with the rapid advancements of China’s biotech sector. This development has sparked a debate on whether protectionist measures are necessary to maintain American leadership in life sciences. Amidst this backdrop, Amgen Inc. (NASDAQ: AMGN) has been actively engaging with the U.S. government to address these challenges and reinforce its commitment to innovation and domestic manufacturing.

Industry Divided Over China’s Biotech Growth

The U.S. biopharmaceutical industry is increasingly divided over how to respond to China’s rapid growth in biotech. At the heart of the debate is whether protectionist measures are necessary to maintain American leadership in life sciences. While conducting early-stage drug development in China is cheaper and faster, and major pharmaceutical companies like Pfizer and Bristol Myers Squibb are investing heavily there, some critics caution that overreliance on Chinese-developed drugs may pose risks. Others argue that engaging with Chinese biotech can benefit U.S. patients by bringing more high-quality treatments to market.

The debate encompasses concerns over national security, financial interests, and healthcare outcomes. Though most agree that protectionism is not a stand-alone solution, there is a consensus on the need to accelerate and streamline the U.S. research and development process. Lawmakers are also involved, with Rep. Moolenaar proposing to include biotech under the COINS Act, which monitors U.S. investments in technologies tied to adversarial nations. The Trump administration has emphasized maintaining U.S. biotech leadership as a top priority, highlighting the geopolitical dimensions of the issue.

Amgen’s Proactive Measures

In response to these industry dynamics, Amgen has taken proactive steps to collaborate with the U.S. government in lowering medicine costs for American patients. This initiative underscores Amgen’s long-standing commitment to investing in innovation and U.S. manufacturing. The company has expanded its direct-to-patient program, AmgenNow™, to include medications like Aimovig® and Amjevita®, offering them at significantly reduced monthly prices. This move aligns with the administration’s Most Favored Nation pricing requests, aiming to make essential medicines more accessible to patients.

Furthermore, Amgen has announced substantial investments in U.S. manufacturing, including expansions of $900 million in Ohio and $1 billion in North Carolina. These investments are facilitated by pro-growth tax policies and are expected to bolster domestic production capabilities, ensuring a stable supply chain and reinforcing the company’s commitment to American innovation.

Financial Performance and Market Position

Amgen’s strategic initiatives are reflected in its robust financial performance. In the fourth quarter of 2025, the company reported a 9% increase in total revenues, reaching $9.9 billion compared to the same period in 2024. This growth was driven by a 10% increase in product sales, primarily due to volume growth. For the full year, total revenues increased by 10% to $36.8 billion, highlighting the company’s strong market position and effective execution of its strategic plans.

As of July 10, 2026, Amgen’s stock price stood at $363.39, with a slight change of 0.09% from the previous close. This stability indicates investor confidence in the company’s direction amidst the evolving biotech landscape.

Conclusion

Amgen’s proactive engagement with the U.S. government and substantial investments in domestic manufacturing position the company as a leader in navigating the complexities of the current biopharmaceutical environment. By focusing on innovation, affordability, and strengthening U.S. manufacturing capabilities, Amgen aims to maintain its competitive edge and contribute to the broader goal of sustaining American leadership in the biotech industry.